AVR.NASDAQAnteris Technologies Global CORP

10-K: Anteris Technologies Global Corp. Navigates Development Stage with Focus on DurAVR THV System

Sentiment:

Annual Report

📋All filings for Anteris Technologies Global CORP
🔒Login to Follow

Anteris Technologies Global Corp.'s 10-K filing highlights its ongoing development of the DurAVR THV system, clinical trial progress, and financial position as a development-stage company.

Capital raiseThe company will require substantial additional future financing and may be unable to raise sufficient capital, which could have a material impact on its R&D programs or commercialization of its products.The company intends to raise funds through the issuance of its capital stock or other securities.
Worse than expectedThe company's operating loss increased from $47.5 million in 2023 to $78.4 million in 2024.The company's net loss increased from $46.8 million in 2023 to $76.0 million in 2024.The company's accumulated deficit increased from $200.1 million in 2023 to $276.4 million in 2024.

Summary

  • Anteris Technologies Global Corp. is focused on revolutionizing cardiac care with its DurAVR THV system for aortic stenosis treatment.
  • The DurAVR THV system is a novel, biomimetic valve made with ADAPT tissue-enhancing technology and deployed with the ComASUR delivery system.
  • As of January 2025, 83 patients have been treated with the DurAVR THV across the United States, Canada, and Europe.
  • The company is planning to submit an IDE for the DurAVR THV system Pivotal Trial to the FDA by the end of quarter one of 2025, with enrollment anticipated to begin in the third quarter of 2025.
  • Anteris is a development stage company and has incurred net losses in each year since operation.
  • The total global market opportunity for TAVR in relation to severe aortic stenosis and in relation to ViV procedures is expected to reach $9.9 billion and $2.5 billion, respectively, in 2028.
  • The company relies on single-source suppliers for certain materials and manufacturing services.
  • Anteris is subject to extensive government regulation, including environmental, health, and safety regulations.
  • The company has identified material weaknesses in its internal control over financial reporting.
  • The independent auditor's report includes an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's progress in clinical trials and market opportunity, the company faces significant financial challenges, including operating losses, going concern uncertainty, and the need for additional funding. The material weaknesses in internal control further dampen the sentiment.

Positives

  • The DurAVR THV system has a novel, biomimetic design that aims to replicate the normal blood flow of a healthy human aortic valve.
  • The ADAPT tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure.
  • The company has a strong intellectual property position with 51 issued patents and 53 pending patent applications.
  • The company has a experienced executive team.
  • The company completed an initial public offering in December 2024, raising $80.1 million in net proceeds.

Negatives

  • The company has a history of operating losses and may not achieve or maintain profitability in the future.
  • There is substantial doubt about the company's ability to continue as a going concern.
  • The company will require substantial additional future financing and may be unable to raise sufficient capital.
  • The company has identified material weaknesses in its internal control over financial reporting.

Risks

  • Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on the company's prospects.
  • The company may find it difficult to enroll patients in its clinical trials.
  • The company operates in a highly competitive and rapidly changing industry.
  • The company relies on third parties to conduct its clinical trials and preclinical studies.
  • The company is subject to various risks relating to international activities that could affect its profitability.
  • Any failure to protect the company's information technology infrastructure and its products against cyber-based attacks could materially disrupt its operations.
  • Increased emphasis on environmental, social, and governance matters may have an adverse effect on the company's business, financial condition, results of operations and reputation.
  • The company could become exposed to product liability claims that could harm its business.
  • The company's products and operations are subject to extensive government regulation.
  • Healthcare policy changes may have a material adverse effect on the company.
  • The company's profitability may be impacted by ongoing coverage and reimbursement determinations by government health care programs and other third-party payors for its products.
  • The company's success depends on its ability to protect its intellectual property and its proprietary technology.
  • The market price and trading volume of the company's Common Stock may be volatile and may be affected by economic conditions beyond its control.
  • An active, liquid trading market for the company's Common Stock may not be maintained.

Future Outlook

The company expects expenses for research, clinical validation, development, design, manufacturing and marketing to increase and, as a result, will need additional capital to fund its operations.

Industry Context

The company competes in the cardiovascular device market, particularly the TAVR market, which is characterized by rapid change resulting from technological advances, innovations and scientific discoveries.

Comparison to Industry Standards

  • The document mentions Edwards Lifesciences Corporation and Medtronic plc as primary competitors.
  • It states that currently, no competitor has a single-piece tissue TAVR commercially available or has publicly disclosed that a single-piece tissue TAVR is in development.

Legal Proceedings

  • The Company has received a legal claim in connection with an equity raise undertaken in 2024 and the subsequent Nasdaq IPO.
  • A provision of $1.4 million has been recognized in relation to this claim.

Stakeholder Impact

  • Shareholders face the risk of dilution from future equity financings.
  • Employees may be affected by potential cost-cutting measures if the company is unable to secure additional funding.
  • Customers and patients may benefit from the successful development and commercialization of the DurAVR THV system.
  • Suppliers and creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

  • The company is currently planning to submit an IDE for the DurAVR THV system Pivotal Trial to the FDA by the end of quarter one of 2025.
  • Subject to FDA approval, the company anticipates enrollment to begin in the Pivotal Trial in the third quarter of 2025.

Key Dates

DateDescription
2011FDA initially approved TAVR for high surgical risk patients.
January 30, 2014CardioCel was cleared for marketing by the FDA as a Class II device.
August 30, 2017Anteris entered into a supply and license agreement with 4C Medical Technologies, Inc.
October 11, 2019Anteris sold the distribution and manufacturing rights to LeMaitre Vascular Inc. for CardioCel and VascuCel products.
2019The FDA also approved TAVR for use in low-risk surgical patients.
April 3, 2020ADAPT tissue was cleared for marketing by the FDA.
March 25, 2020Anteris entered into a services agreement with NPX Medical, LLC.
November 16, 2021Anteris entered into a supply and quality agreement with Aran Biomedical Teoranta.
October 5, 2021Anteris entered into a Master Services Agreement with IQVIA.
November 2021Anteris commenced its FIH study at the Tbilisi Heart and Vascular Clinic in Tbilisi, Georgia.
December 5, 2022Anteris entered into a material development agreement with the Ear Science Institute Australia.
November 2022Anteris received conditional approval of its United States early feasibility study (US EFS) EFS investigational device exemption (IDE) application from the FDA.
March 24, 2023The FDA determined that approval of an IDE supplement is not required to manufacture the DurAVR valve for investigational use in clinical trials at the facility in Minnesota.
April 18, 2023Anteris purchased 30% of the equity capital stock of v2vmedtech.
July 2023The DurAVR THV system was used for the first time in a ViV procedure at the Institut de Cardiologie de Montral in Canada.
August 2023A second Canadian patient was successfully implanted with the DurAVR THV system in a ViV procedure.
December 2023The fourth patient cohort was implanted with the DurAVR THV.
January 2024LeMaitre commenced manufacturing the CardioCel and VascuCel products.
January 29, 2024The Company was incorporated in the State of Delaware.
December 3, 2024The Scheme was approved by ATLs shareholders at a general meeting of shareholders.
December 4, 2024ATL obtained approval of the Scheme and the Option Scheme by the Supreme Court of Queensland.
December 12, 2024The Registration Statement relating to the initial public offering became effective.
December 16, 2024The Reorganization was completed, and the Company issued shares of Common Stock and options to purchase shares of Common Stock.
December 16, 2024The Company received a notice of redemption from Obsidian, requiring that the Company redeem all outstanding Convertible Notes for cash.
December 19, 2024The Company redeemed the outstanding Convertible Notes for an aggregate cash payment of $5.7 million.
December 2024Preparation of the EU EFS commenced, with the activation of the first European Union (EU) investigational site.
December 202412-month follow-up visits were completed in the US EFS.
January 2025The first two subjects were implanted in the EU EFS.
January 2025The Transition Services Agreement with LeMaitre expired.
February 11, 2025The development project under the ESIA Agreement, and therefore the agreement, was terminated.
February 18, 2025The Convertible Note Facility was terminated, and the security interest was released.
End of quarter one of 2025The company is currently planning to submit an IDE for the DurAVR THV system Pivotal Trial to the FDA.
Third quarter of 2025Subject to FDA approval, the company anticipates enrollment to begin in the Pivotal Trial.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.